Mercè Boada, MD, PhD, Fundació ACE, International University of Catalonia, Barcelona, Spain, discusses the launch of the first AMBAR (Alzheimer Management by Albumin Replacement) center by the Ace Alzheimer Center Barcelona and Grifols. The Phase IIb/III AMBAR trial (NCT01561053), reported in 2020, suggested that therapeutic plasma exchange (TPE) with albumin replacement may be able to delay cognitive and functional progression in patients with mild/moderate Alzheimer’s disease. In June 2021, the first AMBAR center was opened in Barcelona, Spain, which will use the procedure in clinical practice to collect real-world data. This interview took place during the European Academy of Neurology 2021 congress.
Prof. Boada reports the following disclosures:
-Grants: La Caixa, Grifols, IMI, ISCII
-Advisory Board: Grifols, Araclon, Biogen, Roche, Lilly, Cortexyme
-Speaker honoraria: Biogen, Roche
-Consulting honoraria: Biogen, Roche, Merck, Cortexyme, Zambón